ATLASENSE BIOMED LTD.

Founded in 2015 and headquartered in Israel, ATLASense is led by a team of world-renowned healthcare and MedTech business experts. ----------------------------------------------------------------------------------------------------------------- During the COVID-19 pandemic, doctors reported that many patients in stable condition suddenly suffered from respiratory failure after a few days, and their oxygen saturation in the blood declined. That led to expensive and problematic treatment, such as ... intubation and ventilation. Well, actually, this respiratory failure does not happen all of a sudden. The deterioration in such lung diseases starts much earlier, and six stages of the decline can be identified. Like the smartphone that revolutionized the way we communicate, ATLASense is proud to present the PolyMonitor, a chest-worn multipurpose platform device that is the game changer for medical monitoring and brings ICU-level health surveillance to home. Based on one device, doctors and healthcare providers will be able to use various clinical monitoring and diagnostic applications for different diseases to provide much better care and safe significant cost-of-care. Here are some examples of our clinical indications: The respiratory deterioration detection problem Many Pulmonary disease patients (ALS, COVID-19, COPD, ARDS, etc.) are reported of sudden respiratory failure and need emergency intubation and mechanical ventilation. These treatments cause complications. Mechanically ventilated patients develop increased complications and frequent long-term damage to the respiratory system. If the development of respiratory failure is detected early, intubation and invasive mechanical ventilation may be prevented. And hence achieve savings in suffering and expenses. Currently, there are no early warning for respiratory failure solutions for the patient except in the ICU. The standard of care is detecting only the changes in the CO2 and O2 saturation in the blood; in-failure already conditions. ATLASense has developed a breakthrough solution for remotely managing respiratory deterioration of hospitalized patients and at home. ATLASense is the only one in the world that develops already-proven solutions to provide healthcare providers with the earliest possible prediction of respiratory failure allowing effective preventive care! We are the only one in the world developing a game-changing product for the hospital at-home market, providing an early warning system for cardiovascular and pulmonary diseases with one small chest-warn wireless PolyMonitor. Enable healthcare providers to save 77% of the care costs or over $300 per day per patient. 1 Billion people's target market may get this subscription service for less the $5 a day per patient. Winner of the 2020 Henry Ford Health System global monitoring competition, ATLASense developed the REPHAEL platform, patented AI-based remote Health near real-time monitoring, empowering healthcare providers' teams to: 1. Prevent premature deaths 2. Reduce treatment costs 3. Improve patients' quality of life 4. Have a profit engine The REPHAEL platform is the only RPM system that enables the earliest possible prediction of: • Heart failure • Respiratory failure • Early signs of Sepsis. All by a single chest-worn PolyMonitor reusable device.More